KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Outstanding
Ratios

Teva Pharmaceutical Industries (TEVA) Short-Term Debt repayments (2016 - 2023)

Historic Short-Term Debt repayments for Teva Pharmaceutical Industries (TEVA) over the last 4 years, with Q4 2023 value amounting to -$900.0 million.

  • Teva Pharmaceutical Industries' Short-Term Debt repayments changed N/A to -$900.0 million in Q4 2023 from the same period last year, while for Dec 2024 it was -$700.0 million, marking a year-over-year decrease of 25000.0%. This contributed to the annual value of -$700.0 million for FY2023, which is N/A changed from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Short-Term Debt repayments stood at -$900.0 million for Q4 2023.
  • Teva Pharmaceutical Industries' Short-Term Debt repayments' 5-year high stood at $500.0 million during Q4 2021, with a 5-year trough of -$900.0 million in Q4 2023.
  • For the 3-year period, Teva Pharmaceutical Industries' Short-Term Debt repayments averaged around $60.8 million, with its median value being $321.5 million (2020).
  • The largest annual percentage gain for Teva Pharmaceutical Industries' Short-Term Debt repayments in the last 5 years was 1286.68% (2021), contrasted with its biggest fall of 1286.68% (2021).
  • Quarter analysis of 3 years shows Teva Pharmaceutical Industries' Short-Term Debt repayments stood at $443.0 million in 2020, then grew by 12.87% to $500.0 million in 2021, then plummeted by 280.0% to -$900.0 million in 2023.
  • Its Short-Term Debt repayments stands at -$900.0 million for Q4 2023, versus $200.0 million for Q3 2023 and $500.0 million for Q4 2021.